创新药ETF国泰（517110）回调近3%，中国原料药企业竞争优势有望继续强化，回调或可布局

Core Viewpoint - The recent decline of nearly 3% in the Cathay Innovation Drug ETF (517110) presents a potential opportunity for investment in Chinese raw material pharmaceutical companies, which are expected to strengthen their competitive advantages [1]. Industry Summary - China's pharmaceutical and healthcare product export value is projected to grow by 3.14% by 2025, with a slight decrease of 0.27% in the export value of Western medicine raw materials [1]. - The stability in raw material drug exports reflects the competitiveness of China's raw material pharmaceutical industry amidst global trade changes and internal price competition [1]. - The outlook for 2026 indicates continued uncertainty in raw material trade, driven by price competition and advancements in synthetic biology and new production technologies that lower unit costs [1]. - Upgrades in technology are enhancing the global competitiveness of Chinese raw material pharmaceutical companies [1]. - A trend of supply clearing is ongoing, with some product prices continuing to decline; however, the potential for significant further price drops is limited compared to historical averages [1]. - Price competition pressures are beginning to impact the profits of leading companies [1]. - The competitive advantages of Chinese raw material pharmaceutical companies are expected to strengthen by 2026, with some product prices having likely bottomed out, leading to potential price recovery due to changes in competitive dynamics and production capacity utilization [1]. Company Summary - The Cathay Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which focuses on publicly listed companies engaged in the research, production, and sales of innovative drugs in the Shanghai, Shenzhen, and Hong Kong markets [1].